WCN26-4959 CARDIOMETABOLIC MANAGEMENT AND PRESCRIPTION OF KIDNEY-PROTECTIVE AGENTS AMONG THAI PATIENTS WITH CKD: INSIGHTS FROM THE THAI CKD PROJECT

Read full text Summarise with VIRAT
Authors: Kavita Jintanapramote, Thatsaphan Srithongkul, Thananda Trakarnvanich, Juthamash Sangsuk, Sirirat Asawamethapant, Jathurong Kittrakulrat, Tossaporn Sapsitthikul, Narittaya Varothai, Sirirat Anutrakulchai, Chanchana Boonyakrai, Kajohnsak Noppakun, Wonngarm Kittanamongkolchai
+3 more Talerngsak Kanjanabuch, Vuddhidej Ophascharoensuk, Paweena Susantitaphong
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cardiometabolic risk control and the use of kidney-protective treatments are central to slowing CKD progression. Current guidelines emphasize four pillars of therapy: renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and non-steroidal mineralocorticoid receptor antagonists (ns-MRA). The ns-MRA were not yet available in Thailand during the study period. This study evaluated cardiometabolic control and the uptake of kidney-protective agents among Thai CKD patients.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Acute Kidney Injury Research Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106016–106016
Publication date
25 March 2026
Language
EN